Is Cronos Group (CRON) a Buy right now?

: CRON | Cronos Group Inc. - Common Share News, Ratings, and Charts

CRON – We are taking a close look at Cronos group today to see if now is the time to buy the dip in shares of the company.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

If you are a new cannabis investor just getting into the market, or a seasoned veteran, it seems as if everything is on sale right now. Although we never really know when the market is at a bottom or how long it will continue to decline, one strategy that has worked has been to consistently buy the large caps in a specific sector, and incrementally add to your positions as the market declines. Eventually, when the market stabilizes, you will have purchased additional shares and brought your average cost down substantially. For the cannabis sector, it has been a harsh spring and summer with most companies facing declines across the board. As the market retests December lows, we need to take a look at which companies are best positioned for a rebound when the market picks back up.

We are taking a close look at Cronos group today to see if now is the time to buy the dip in shares of the company. In the second quarter, Cronos sold a total of 1,584 kilos up from 1,111 kilos in the first quarter. When it comes to cost per gram Cronos outperformed its peers, with an average net selling price for dried cannabis climbing to $6.19/gram from $5.14/gram. The average net selling price of oils rose to $7.69 from $7.16/gram. When it comes to margins, Cronos Group is looking pretty good. Cronos recorded 10.2 million in revenue last quarter which does translate into a lofty valuation compared to its peers.

Looking closer at Cronos to determine why someone might consider this stock over its competitors comes down to two things for us. We see value in the partnership Cronos has with Altria group and the ability to leverage their deeply rooted distribution network when the time is right. This is old news, but we still feel that this carries a premium next to its competitors. The second reason one might consider Cronos is for the simple fact that they are betting big on CBD in America. Cronos recently acquired redwood holdings group which owns a premium CBD brand lord jones. When it comes to first-mover advantage, we feel that having deep-rooted brands under their belt is one way to dominate the market and the acquisition of redwood holdings looks promising for Cronos.

We remain cautiously optimistic when it comes to shares of Cronos. As mentioned earlier we love their partnership with Altria group along with their entry into the CBD market through their acquisition of redwood holdings, but at the same time remain concerned about valuations despite the stock losing over 50% since their peak. At $14 per share the company looks attractive in our books but moving closer to $10 we can get a lot more excited about Cronos. We recommend a wait and see approach if you are interested in shares of Cronos, or a timed incremental buying approach if Cronos is a must-have today. Patience and timed buying should be able to catch the bottom but for now, Cronos still has some proving to do.


CRON shares were trading at $12.23 per share on Friday morning, up $0.65 (+5.61%). Year-to-date, CRON has gained 17.71%, versus a 20.44% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CRONGet RatingGet RatingGet Rating
CGCGet RatingGet RatingGet Rating
ACBGet RatingGet RatingGet Rating
GNLNGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating
TLRYGet RatingGet RatingGet Rating
CTSTGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Top Stories on StockNews.com

NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

The Correct Mindset to Have After the Stock Market Plummets

Today's featured article covers the correct mindset to have after the stock market plummets, which includes the SPDR S&P 500 ETF Trust (NYSEARCA: SPY). Continue reading for all the important details.
: ACB | Aurora Cannabis Inc. Common Shares News, Ratings, and Charts

Cannabis Stocks: The Week in Review

The cannabis sector hit fresh 52 week-lows and many are wondering when it will reach a bottom
NYSE: VXX | iPath Series B S&P 500 VIX Short-Term Futures ETN News, Ratings, and Charts

Volatility Is Skyrocketing: What the VIX Is and How to Trade it

Today's featured article covers what the CBOE Volatility Index (INDEXCBOE: VIX) is and how to trade it. Continue reading for all the important details.
NASDAQ: GWPH | GW Pharmaceuticals Plc News, Ratings, and Charts

Why Did GW Pharmaceuticals (GWPH) Drop 18% This Week?

GWPH also substantially improved its bottom from the prior-year quarter.  The company posted a net loss of $71.9 million which equates to $0.20 per share
NASDAQ: NTES | NetEase, Inc., each representing 25 ordinary shares News, Ratings, and Charts

3 Shocking Strong Buy Upgrades

Why did NTES, COUP and CNNE rise to Strong Buy ratings when most other stocks are faltering? Get the answer below...

Read More Stories


More Cronos Group Inc. - Common Share (CRON) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CRON News
Page generated in 1.7132 seconds.